The Joint Corp.

NASDAQ:JYNT

Medical - Care Facilities

Healthcare
$6.65 +1.86%

+$0.17 today

Market cap
$91.03M
Beta
1.10
P/E (TTM)
40.7
EPS (TTM)
$0.23
52W Low $7.50High $13.00

Volume 0.05M

Average 0.07M

JYNT EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

The Joint Corp.NASDAQ: JYNT

EBITDA · Q1 FY2026 · quarter ended Mar 2026

EBITDA turns positive

Q1 FY2026 EBITDA was $1.51M, compared with -$288.25K a year earlier. Trailing-twelve-month EBITDA was $2.94M. Over 3 fiscal years it compounded at -42.7% a year.

Context

  • EBITDA amounted to 2.7% of revenue in FY2025, down 2.9 pp from a year earlier.
  • EBITDA increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether EBITDA reaches the consensus estimate from 3 analysts of $6.73M (+353.5%) for the fiscal year ending Dec 2026, a step up from the -48.8% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$1.51M+9.2% QoQ
Last fiscal yearDec 2025
$1.48M-48.8% YoY
LTMMar 2026
$2.94M+2328.8% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+624.1%+276.6%-347.5 pp
1 year-48.8%+353.5%+402.3 pp
3-year CAGR-42.7%+18.0%+60.7 pp
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

USD · from the income statement

Latest · FY2025
1.48M USD
Year-over-year change
-48.8%
4-year CAGR
-38.0%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How JYNT compares with its peers on the latest reported figures

  • JYNT's LTM Mar 2026 EBITDA of $2.94M is the 3rd highest of the 11 companies compared; the peer median is -$37.67M.
  • Its year-over-year change of +2328.8% is the highest of 11, against a peer median of -2.9%.
  • EBITDA amounts to 5.2% of revenue for JYNT, versus a peer median of 91.5%.
JYNT Competitors Peer median
EBITDA for JYNT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BTMDbiote Corp.LTM Mar 2026$37.29M -29.9%+88.3%19.8%
CCLDCareCloud, Inc.LTM Mar 2026$28.3M +17.2%+10.4%22.8%
JYNTThe Joint Corp.LTM Mar 2026$2.94M +2328.8%-42.7%5.2%
APYXApyx Medical CorporationLTM Mar 2026-$2.44M +81.8%—4.4%
CGTXCognition Therapeutics, Inc.LTM Mar 2026-$19.31M +41.5%——
SERASera Prognostics, Inc.LTM Mar 2026-$31.22M +2.8%—54764.9%
LUCDLucid Diagnostics Inc.LTM Mar 2026-$44.12M +27.6%—859.3%
RPIDRapid Micro Biosystems, Inc.LTM Mar 2026-$45.12M -8.6%—131.2%
IKTInhibikase Therapeutics, Inc.LTM Mar 2026-$53.92M -39.7%——
DCGODocGo Inc.LTM Mar 2026-$156.43M -1199.8%—51.8%
STSSSkyAI, Inc.LTM Mar 2026-$341.95M -5893.3%—86155.0%
Peer median (excluding JYNT) -$37.67M-2.9%+49.3%91.5%

Competitors are the stored peer set for JYNT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue80.01M101.25M46.98M52.16M54.9M
Cost of Revenue7.67M9.17M10.48M11.52M11.23M
Gross Profit72.35M92.08M36.5M40.65M43.67M
Gross Margin90.4%90.9%77.7%77.9%79.6%
Research & Development00000
Selling, General & Admin62.27M81.95M34.92M41.1M42.93M
Operating Expenses66.22M91.25M36.18M42.54M44.58M
Depreciation & Amortization3.92M6.65M8.58M4.72M1.71M
EBITDA10.07M7.89M8.88M2.9M1.48M
EBITDA Margin12.6%7.8%18.9%5.6%2.7%
Operating Income6.13M828.25K318.3K(1.89M)(905.48K)
Operating Margin7.7%0.8%0.7%-3.6%-1.6%
Interest Income0133.1K0280.29K0
Interest Expense0953.53K64.29K00
Other Income / Expenses(69.88K)(133.1K)(64.29K)280.29K675.97K
Income Before Tax6.06M695.15K254.01K(1.61M)(229.5K)
Pre-Tax Margin7.6%0.7%0.5%-3.1%-0.4%
Income Tax Expense(1.51M)68.45K11.02M5.61K38.65K
Net Income7.57M626.71K(9.75M)(5.8M)2.91M
Net Margin9.5%0.6%-20.8%-11.1%5.3%
EPS (Basic)0.460.04(0.66)(0.39)0.19
EPS (Diluted)0.440.04(0.66)(0.39)0.19
Weighted Avg Shares14.32M14.49M14.69M14.92M15.13M
Weighted Avg Shares (Diluted)14.94M14.87M14.69M15.15M15.13M

The Joint Corp.

NASDAQ:JYNT

Intrinsic Alpha fair value

Locked

Current Price

$6.65

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.